# Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects

> **NCT03794180** · PHASE1 · COMPLETED · sponsor: **I-Mab Biopharma US Limited** · enrollment: 32 (actual)

## Conditions studied

- Healthy Adult Subjects

## Interventions

- **DRUG:** TJ003234
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03794180
- **Lead sponsor:** I-Mab Biopharma US Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-18
- **Primary completion:** 2019-09-05
- **Final completion:** 2019-09-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03794180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03794180, "Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT03794180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*